Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir With or Without Ribavirin (RBV) in Adult Patients With GT1 or GT4 Chronic HCV Infection and Response to Prior Treatment of Early Stage Hepatocellular Carcinoma (GEODE - I)
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms GEODE - I
- Sponsors AbbVie
- 13 Nov 2017 Status changed to discontinued due to low enrollment
- 03 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.
- 08 Mar 2016 Planned End Date changed from 1 Mar 2020 to 1 Dec 2016 as reported by ClinicalTrials.gov record.